I4V-MC-JAJK: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to
Phase 3 – large-scale trial before approval
Conditions:
Diabetes Mellitus
Type 1
Sponsor: Eli Lilly & Co.
trial.available_in:
БГ
Overview
Trial status: Authorised
Change from Baseline in C-peptide Area Under the Curve (AUC) [Time Frame: Baseline, Week 52]
Who can participate
Age group: 18-64 years, 0-17 years
Gender: Female, Male
Target enrollment: 183 participants
БГ